Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Werewolf Therapeutics Inc is a biotechnology business based in the US. Werewolf Therapeutics shares (HOWL) are listed on the NASDAQ and all prices are listed in US Dollars. Werewolf Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$15.37|
|52-week range||$11.23 - $21.67|
|50-day moving average||$17.03|
|200-day moving average||$15.82|
|Wall St. target price||$26.40|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-36.98|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-5.42%|
|1 month (2021-09-27)||-11.92%|
|3 months (2021-07-27)||-18.50%|
|6 months (2021-04-23)||N/A|
|1 year (2020-10-23)||N/A|
|2 years (2019-10-23)||N/A|
|3 years (2018-10-23)||N/A|
|5 years (2016-10-23)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-23.72%|
|Return on equity TTM||-30.39%|
|Market capitalisation||$446.3 million|
TTM: trailing 12 months
There are currently 663,251 Werewolf Therapeutics shares held short by investors – that's known as Werewolf Therapeutics's "short interest". This figure is 2% down from 676,614 last month.
There are a few different ways that this level of interest in shorting Werewolf Therapeutics shares can be evaluated.
Werewolf Therapeutics's "short interest ratio" (SIR) is the quantity of Werewolf Therapeutics shares currently shorted divided by the average quantity of Werewolf Therapeutics shares traded daily (recently around 15243.645139048). Werewolf Therapeutics's SIR currently stands at 43.51. In other words for every 100,000 Werewolf Therapeutics shares traded daily on the market, roughly 43510 shares are currently held short.
To gain some more context, you can compare Werewolf Therapeutics's short interest ratio against those of similar companies.
However Werewolf Therapeutics's short interest can also be evaluated against the total number of Werewolf Therapeutics shares, or, against the total number of tradable Werewolf Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Werewolf Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Werewolf Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0347% of the tradable shares (for every 100,000 tradable Werewolf Therapeutics shares, roughly 35 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Werewolf Therapeutics.
Find out more about how you can short Werewolf Therapeutics stock.
We're not expecting Werewolf Therapeutics to pay a dividend over the next 12 months.
Werewolf Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, with the help of its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing Valkyrie Bitcoin Strategy ETF units.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.